These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1032 related articles for article (PubMed ID: 26802084)

  • 21. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
    Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
    Hisamatsu T; Matsumoto T; Watanabe K; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2019 Sep; 13(9):1097-1104. PubMed ID: 30753377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
    R-Grau Mdel C; Chaparro M; Mesonero F; Barreiro-de Acosta M; Castro L; Castro M; Domènech E; Mancenido N; Pérez-Calle JL; Taxonera C; Barrio J; De Francisco R; Fernández-Salgado E; Luzón L; Merino O; Oltra L; Saro C; Bermejo F; García-Sánchez V; Ginard D; Gutiérrez A; Vera I; Antón R; Ber Y; Calvet X; Gisbert JP
    Dig Liver Dis; 2016 Jun; 48(6):613-9. PubMed ID: 26992847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
    Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
    J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
    Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
    J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
    J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease.
    Taxonera C; Barreiro-de-Acosta M; Bastida G; Martinez-Gonzalez J; Merino O; García-Sánchez V; Gisbert JP; Marín-Jiménez I; López-Serrano P; Gómez-García M; Iglesias E; Lopez-Sanroman A; Chaparro M; Saro C; Bermejo F; Pérez-Carazo L; Plaza R; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    J Crohns Colitis; 2016 Jun; 10(6):657-62. PubMed ID: 26786982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
    Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE; Kamm MA; Hartono JL; Lust M
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
    Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
    Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
    Magro F; Santos-Antunes J; Vilas-Boas F; Rodrigues-Pinto E; Coelho R; Ribeiro OS; Lopes S; Macedo G
    J Crohns Colitis; 2014 Jul; 8(7):617-25. PubMed ID: 24332869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study.
    Kobayashi T; Hishida A; Tanaka H; Nuki Y; Bamba S; Yamada A; Fujii T; Shinzaki S; Yokoyama Y; Yoshida A; Ozeki K; Ashizuka S; Kamata N; Nanjo S; Kakimoto K; Nakamura M; Matsui A; Yamauchi R; Takahashi S; Tomizawa T; Yoshino T; Hibi T
    Inflamm Bowel Dis; 2017 Dec; 23(12):2245-2251. PubMed ID: 29084079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vulval Crohn's disease: a clinical study of 22 patients.
    Laftah Z; Bailey C; Zaheri S; Setterfield J; Fuller LC; Lewis F
    J Crohns Colitis; 2015 Apr; 9(4):318-25. PubMed ID: 25687208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
    Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.